Pharma & Healthcare

Global Dermatomycoses Drug Market Insights and Forecast to 2028

Global Dermatomycoses Drug Market Insights and Forecast to 2028

Dermatomycoses Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Dermatomycoses Drug market will be able to gain the upper hand as they u...

  • ID: QYR81335
  • Published: Apr 2022
  • Pages: 112
  • Format: PDF
  • Industry: Pharma & Healthcare
Dermatomycoses Drug market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Dermatomycoses Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type
BB-2603
Clotrimazole
Dapaconazole
Others

Segment by Application
Hospital
Clinic
Others

By Company
Anacor Pharmaceuticals Inc
Biolab Farmaceutica Ltda
Blueberry Therapeutics Ltd
Daewoong Pharmaceutical Co Ltd
Dermala Inc
Helix BioMedix Inc
Novan Inc
Sol-Gel Technologies Ltd
TGV-Laboratories
Viamet Pharmaceuticals Inc
Vyome Biosciences Pvt Ltd

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Table of Content
1 Study Coverage
1.1 Dermatomycoses Drug Product Introduction
1.2 Market by Type
1.2.1 Global Dermatomycoses Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 BB-2603
1.2.3 Clotrimazole
1.2.4 Dapaconazole
1.2.5 Others
1.3 Market by Application
1.3.1 Global Dermatomycoses Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Dermatomycoses Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Dermatomycoses Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Dermatomycoses Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Dermatomycoses Drug Sales by Region
2.4.1 Global Dermatomycoses Drug Sales by Region (2017-2022)
2.4.2 Global Sales Dermatomycoses Drug by Region (2023-2028)
2.5 Global Dermatomycoses Drug Revenue by Region
2.5.1 Global Dermatomycoses Drug Revenue by Region (2017-2022)
2.5.2 Global Dermatomycoses Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Dermatomycoses Drug Sales by Manufacturers
3.1.1 Global Top Dermatomycoses Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Dermatomycoses Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Dermatomycoses Drug in 2021
3.2 Global Dermatomycoses Drug Revenue by Manufacturers
3.2.1 Global Dermatomycoses Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Dermatomycoses Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Dermatomycoses Drug Revenue in 2021
3.3 Global Dermatomycoses Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Dermatomycoses Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Dermatomycoses Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Dermatomycoses Drug Sales by Type
4.1.1 Global Dermatomycoses Drug Historical Sales by Type (2017-2022)
4.1.2 Global Dermatomycoses Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Dermatomycoses Drug Sales Market Share by Type (2017-2028)
4.2 Global Dermatomycoses Drug Revenue by Type
4.2.1 Global Dermatomycoses Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Dermatomycoses Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Dermatomycoses Drug Revenue Market Share by Type (2017-2028)
4.3 Global Dermatomycoses Drug Price by Type
4.3.1 Global Dermatomycoses Drug Price by Type (2017-2022)
4.3.2 Global Dermatomycoses Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Dermatomycoses Drug Sales by Application
5.1.1 Global Dermatomycoses Drug Historical Sales by Application (2017-2022)
5.1.2 Global Dermatomycoses Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Dermatomycoses Drug Sales Market Share by Application (2017-2028)
5.2 Global Dermatomycoses Drug Revenue by Application
5.2.1 Global Dermatomycoses Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Dermatomycoses Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Dermatomycoses Drug Revenue Market Share by Application (2017-2028)
5.3 Global Dermatomycoses Drug Price by Application
5.3.1 Global Dermatomycoses Drug Price by Application (2017-2022)
5.3.2 Global Dermatomycoses Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Dermatomycoses Drug Market Size by Type
6.1.1 North America Dermatomycoses Drug Sales by Type (2017-2028)
6.1.2 North America Dermatomycoses Drug Revenue by Type (2017-2028)
6.2 North America Dermatomycoses Drug Market Size by Application
6.2.1 North America Dermatomycoses Drug Sales by Application (2017-2028)
6.2.2 North America Dermatomycoses Drug Revenue by Application (2017-2028)
6.3 North America Dermatomycoses Drug Market Size by Country
6.3.1 North America Dermatomycoses Drug Sales by Country (2017-2028)
6.3.2 North America Dermatomycoses Drug Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Dermatomycoses Drug Market Size by Type
7.1.1 Europe Dermatomycoses Drug Sales by Type (2017-2028)
7.1.2 Europe Dermatomycoses Drug Revenue by Type (2017-2028)
7.2 Europe Dermatomycoses Drug Market Size by Application
7.2.1 Europe Dermatomycoses Drug Sales by Application (2017-2028)
7.2.2 Europe Dermatomycoses Drug Revenue by Application (2017-2028)
7.3 Europe Dermatomycoses Drug Market Size by Country
7.3.1 Europe Dermatomycoses Drug Sales by Country (2017-2028)
7.3.2 Europe Dermatomycoses Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Dermatomycoses Drug Market Size by Type
8.1.1 Asia Pacific Dermatomycoses Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Dermatomycoses Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Dermatomycoses Drug Market Size by Application
8.2.1 Asia Pacific Dermatomycoses Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Dermatomycoses Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Dermatomycoses Drug Market Size by Region
8.3.1 Asia Pacific Dermatomycoses Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Dermatomycoses Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Dermatomycoses Drug Market Size by Type
9.1.1 Latin America Dermatomycoses Drug Sales by Type (2017-2028)
9.1.2 Latin America Dermatomycoses Drug Revenue by Type (2017-2028)
9.2 Latin America Dermatomycoses Drug Market Size by Application
9.2.1 Latin America Dermatomycoses Drug Sales by Application (2017-2028)
9.2.2 Latin America Dermatomycoses Drug Revenue by Application (2017-2028)
9.3 Latin America Dermatomycoses Drug Market Size by Country
9.3.1 Latin America Dermatomycoses Drug Sales by Country (2017-2028)
9.3.2 Latin America Dermatomycoses Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Dermatomycoses Drug Market Size by Type
10.1.1 Middle East and Africa Dermatomycoses Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Dermatomycoses Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Dermatomycoses Drug Market Size by Application
10.2.1 Middle East and Africa Dermatomycoses Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Dermatomycoses Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Dermatomycoses Drug Market Size by Country
10.3.1 Middle East and Africa Dermatomycoses Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Dermatomycoses Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Anacor Pharmaceuticals Inc
11.1.1 Anacor Pharmaceuticals Inc Corporation Information
11.1.2 Anacor Pharmaceuticals Inc Overview
11.1.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Anacor Pharmaceuticals Inc Recent Developments
11.2 Biolab Farmaceutica Ltda
11.2.1 Biolab Farmaceutica Ltda Corporation Information
11.2.2 Biolab Farmaceutica Ltda Overview
11.2.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Biolab Farmaceutica Ltda Recent Developments
11.3 Blueberry Therapeutics Ltd
11.3.1 Blueberry Therapeutics Ltd Corporation Information
11.3.2 Blueberry Therapeutics Ltd Overview
11.3.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Blueberry Therapeutics Ltd Recent Developments
11.4 Daewoong Pharmaceutical Co Ltd
11.4.1 Daewoong Pharmaceutical Co Ltd Corporation Information
11.4.2 Daewoong Pharmaceutical Co Ltd Overview
11.4.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Daewoong Pharmaceutical Co Ltd Recent Developments
11.5 Dermala Inc
11.5.1 Dermala Inc Corporation Information
11.5.2 Dermala Inc Overview
11.5.3 Dermala Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Dermala Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Dermala Inc Recent Developments
11.6 Helix BioMedix Inc
11.6.1 Helix BioMedix Inc Corporation Information
11.6.2 Helix BioMedix Inc Overview
11.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Helix BioMedix Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Helix BioMedix Inc Recent Developments
11.7 Novan Inc
11.7.1 Novan Inc Corporation Information
11.7.2 Novan Inc Overview
11.7.3 Novan Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Novan Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Novan Inc Recent Developments
11.8 Sol-Gel Technologies Ltd
11.8.1 Sol-Gel Technologies Ltd Corporation Information
11.8.2 Sol-Gel Technologies Ltd Overview
11.8.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Sol-Gel Technologies Ltd Recent Developments
11.9 TGV-Laboratories
11.9.1 TGV-Laboratories Corporation Information
11.9.2 TGV-Laboratories Overview
11.9.3 TGV-Laboratories Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 TGV-Laboratories Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 TGV-Laboratories Recent Developments
11.10 Viamet Pharmaceuticals Inc
11.10.1 Viamet Pharmaceuticals Inc Corporation Information
11.10.2 Viamet Pharmaceuticals Inc Overview
11.10.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Viamet Pharmaceuticals Inc Recent Developments
11.11 Vyome Biosciences Pvt Ltd
11.11.1 Vyome Biosciences Pvt Ltd Corporation Information
11.11.2 Vyome Biosciences Pvt Ltd Overview
11.11.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Vyome Biosciences Pvt Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Dermatomycoses Drug Industry Chain Analysis
12.2 Dermatomycoses Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Dermatomycoses Drug Production Mode & Process
12.4 Dermatomycoses Drug Sales and Marketing
12.4.1 Dermatomycoses Drug Sales Channels
12.4.2 Dermatomycoses Drug Distributors
12.5 Dermatomycoses Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Dermatomycoses Drug Industry Trends
13.2 Dermatomycoses Drug Market Drivers
13.3 Dermatomycoses Drug Market Challenges
13.4 Dermatomycoses Drug Market Restraints
14 Key Findings in The Global Dermatomycoses Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Tables and Figures
List of Tables
Table 1. Global Dermatomycoses Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of BB-2603
Table 3. Major Manufacturers of Clotrimazole
Table 4. Major Manufacturers of Dapaconazole
Table 5. Major Manufacturers of Others
Table 6. Global Dermatomycoses Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Dermatomycoses Drug Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Dermatomycoses Drug Sales by Region (2017-2022) & (K Units)
Table 9. Global Dermatomycoses Drug Sales Market Share by Region (2017-2022)
Table 10. Global Dermatomycoses Drug Sales by Region (2023-2028) & (K Units)
Table 11. Global Dermatomycoses Drug Sales Market Share by Region (2023-2028)
Table 12. Global Dermatomycoses Drug Revenue by Region (2017-2022) & (US$ Million)
Table 13. Global Dermatomycoses Drug Revenue Market Share by Region (2017-2022)
Table 14. Global Dermatomycoses Drug Revenue by Region (2023-2028) & (US$ Million)
Table 15. Global Dermatomycoses Drug Revenue Market Share by Region (2023-2028)
Table 16. Global Dermatomycoses Drug Sales by Manufacturers (2017-2022) & (K Units)
Table 17. Global Dermatomycoses Drug Sales Share by Manufacturers (2017-2022)
Table 18. Global Dermatomycoses Drug Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 19. Global Dermatomycoses Drug Revenue Share by Manufacturers (2017-2022)
Table 20. Dermatomycoses Drug Price by Manufacturers (2017-2022) &(USD/Unit)
Table 21. Global Dermatomycoses Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Dermatomycoses Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Dermatomycoses Drug as of 2021)
Table 23. Dermatomycoses Drug Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Dermatomycoses Drug Product Offered
Table 25. Date of Manufacturers Enter into Dermatomycoses Drug Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Dermatomycoses Drug Sales by Type (2017-2022) & (K Units)
Table 28. Global Dermatomycoses Drug Sales by Type (2023-2028) & (K Units)
Table 29. Global Dermatomycoses Drug Sales Share by Type (2017-2022)
Table 30. Global Dermatomycoses Drug Sales Share by Type (2023-2028)
Table 31. Global Dermatomycoses Drug Revenue by Type (2017-2022) & (US$ Million)
Table 32. Global Dermatomycoses Drug Revenue by Type (2023-2028) & (US$ Million)
Table 33. Global Dermatomycoses Drug Revenue Share by Type (2017-2022)
Table 34. Global Dermatomycoses Drug Revenue Share by Type (2023-2028)
Table 35. Dermatomycoses Drug Price by Type (2017-2022) & (USD/Unit)
Table 36. Global Dermatomycoses Drug Price Forecast by Type (2023-2028) & (USD/Unit)
Table 37. Global Dermatomycoses Drug Sales by Application (2017-2022) & (K Units)
Table 38. Global Dermatomycoses Drug Sales by Application (2023-2028) & (K Units)
Table 39. Global Dermatomycoses Drug Sales Share by Application (2017-2022)
Table 40. Global Dermatomycoses Drug Sales Share by Application (2023-2028)
Table 41. Global Dermatomycoses Drug Revenue by Application (2017-2022) & (US$ Million)
Table 42. Global Dermatomycoses Drug Revenue by Application (2023-2028) & (US$ Million)
Table 43. Global Dermatomycoses Drug Revenue Share by Application (2017-2022)
Table 44. Global Dermatomycoses Drug Revenue Share by Application (2023-2028)
Table 45. Dermatomycoses Drug Price by Application (2017-2022) & (USD/Unit)
Table 46. Global Dermatomycoses Drug Price Forecast by Application (2023-2028) & (USD/Unit)
Table 47. North America Dermatomycoses Drug Sales by Type (2017-2022) & (K Units)
Table 48. North America Dermatomycoses Drug Sales by Type (2023-2028) & (K Units)
Table 49. North America Dermatomycoses Drug Revenue by Type (2017-2022) & (US$ Million)
Table 50. North America Dermatomycoses Drug Revenue by Type (2023-2028) & (US$ Million)
Table 51. North America Dermatomycoses Drug Sales by Application (2017-2022) & (K Units)
Table 52. North America Dermatomycoses Drug Sales by Application (2023-2028) & (K Units)
Table 53. North America Dermatomycoses Drug Revenue by Application (2017-2022) & (US$ Million)
Table 54. North America Dermatomycoses Drug Revenue by Application (2023-2028) & (US$ Million)
Table 55. North America Dermatomycoses Drug Sales by Country (2017-2022) & (K Units)
Table 56. North America Dermatomycoses Drug Sales by Country (2023-2028) & (K Units)
Table 57. North America Dermatomycoses Drug Revenue by Country (2017-2022) & (US$ Million)
Table 58. North America Dermatomycoses Drug Revenue by Country (2023-2028) & (US$ Million)
Table 59. Europe Dermatomycoses Drug Sales by Type (2017-2022) & (K Units)
Table 60. Europe Dermatomycoses Drug Sales by Type (2023-2028) & (K Units)
Table 61. Europe Dermatomycoses Drug Revenue by Type (2017-2022) & (US$ Million)
Table 62. Europe Dermatomycoses Drug Revenue by Type (2023-2028) & (US$ Million)
Table 63. Europe Dermatomycoses Drug Sales by Application (2017-2022) & (K Units)
Table 64. Europe Dermatomycoses Drug Sales by Application (2023-2028) & (K Units)
Table 65. Europe Dermatomycoses Drug Revenue by Application (2017-2022) & (US$ Million)
Table 66. Europe Dermatomycoses Drug Revenue by Application (2023-2028) & (US$ Million)
Table 67. Europe Dermatomycoses Drug Sales by Country (2017-2022) & (K Units)
Table 68. Europe Dermatomycoses Drug Sales by Country (2023-2028) & (K Units)
Table 69. Europe Dermatomycoses Drug Revenue by Country (2017-2022) & (US$ Million)
Table 70. Europe Dermatomycoses Drug Revenue by Country (2023-2028) & (US$ Million)
Table 71. Asia Pacific Dermatomycoses Drug Sales by Type (2017-2022) & (K Units)
Table 72. Asia Pacific Dermatomycoses Drug Sales by Type (2023-2028) & (K Units)
Table 73. Asia Pacific Dermatomycoses Drug Revenue by Type (2017-2022) & (US$ Million)
Table 74. Asia Pacific Dermatomycoses Drug Revenue by Type (2023-2028) & (US$ Million)
Table 75. Asia Pacific Dermatomycoses Drug Sales by Application (2017-2022) & (K Units)
Table 76. Asia Pacific Dermatomycoses Drug Sales by Application (2023-2028) & (K Units)
Table 77. Asia Pacific Dermatomycoses Drug Revenue by Application (2017-2022) & (US$ Million)
Table 78. Asia Pacific Dermatomycoses Drug Revenue by Application (2023-2028) & (US$ Million)
Table 79. Asia Pacific Dermatomycoses Drug Sales by Region (2017-2022) & (K Units)
Table 80. Asia Pacific Dermatomycoses Drug Sales by Region (2023-2028) & (K Units)
Table 81. Asia Pacific Dermatomycoses Drug Revenue by Region (2017-2022) & (US$ Million)
Table 82. Asia Pacific Dermatomycoses Drug Revenue by Region (2023-2028) & (US$ Million)
Table 83. Latin America Dermatomycoses Drug Sales by Type (2017-2022) & (K Units)
Table 84. Latin America Dermatomycoses Drug Sales by Type (2023-2028) & (K Units)
Table 85. Latin America Dermatomycoses Drug Revenue by Type (2017-2022) & (US$ Million)
Table 86. Latin America Dermatomycoses Drug Revenue by Type (2023-2028) & (US$ Million)
Table 87. Latin America Dermatomycoses Drug Sales by Application (2017-2022) & (K Units)
Table 88. Latin America Dermatomycoses Drug Sales by Application (2023-2028) & (K Units)
Table 89. Latin America Dermatomycoses Drug Revenue by Application (2017-2022) & (US$ Million)
Table 90. Latin America Dermatomycoses Drug Revenue by Application (2023-2028) & (US$ Million)
Table 91. Latin America Dermatomycoses Drug Sales by Country (2017-2022) & (K Units)
Table 92. Latin America Dermatomycoses Drug Sales by Country (2023-2028) & (K Units)
Table 93. Latin America Dermatomycoses Drug Revenue by Country (2017-2022) & (US$ Million)
Table 94. Latin America Dermatomycoses Drug Revenue by Country (2023-2028) & (US$ Million)
Table 95. Middle East and Africa Dermatomycoses Drug Sales by Type (2017-2022) & (K Units)
Table 96. Middle East and Africa Dermatomycoses Drug Sales by Type (2023-2028) & (K Units)
Table 97. Middle East and Africa Dermatomycoses Drug Revenue by Type (2017-2022) & (US$ Million)
Table 98. Middle East and Africa Dermatomycoses Drug Revenue by Type (2023-2028) & (US$ Million)
Table 99. Middle East and Africa Dermatomycoses Drug Sales by Application (2017-2022) & (K Units)
Table 100. Middle East and Africa Dermatomycoses Drug Sales by Application (2023-2028) & (K Units)
Table 101. Middle East and Africa Dermatomycoses Drug Revenue by Application (2017-2022) & (US$ Million)
Table 102. Middle East and Africa Dermatomycoses Drug Revenue by Application (2023-2028) & (US$ Million)
Table 103. Middle East and Africa Dermatomycoses Drug Sales by Country (2017-2022) & (K Units)
Table 104. Middle East and Africa Dermatomycoses Drug Sales by Country (2023-2028) & (K Units)
Table 105. Middle East and Africa Dermatomycoses Drug Revenue by Country (2017-2022) & (US$ Million)
Table 106. Middle East and Africa Dermatomycoses Drug Revenue by Country (2023-2028) & (US$ Million)
Table 107. Anacor Pharmaceuticals Inc Corporation Information
Table 108. Anacor Pharmaceuticals Inc Description and Major Businesses
Table 109. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 110. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. Anacor Pharmaceuticals Inc Recent Developments
Table 112. Biolab Farmaceutica Ltda Corporation Information
Table 113. Biolab Farmaceutica Ltda Description and Major Businesses
Table 114. Biolab Farmaceutica Ltda Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 115. Biolab Farmaceutica Ltda Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. Biolab Farmaceutica Ltda Recent Developments
Table 117. Blueberry Therapeutics Ltd Corporation Information
Table 118. Blueberry Therapeutics Ltd Description and Major Businesses
Table 119. Blueberry Therapeutics Ltd Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 120. Blueberry Therapeutics Ltd Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Blueberry Therapeutics Ltd Recent Developments
Table 122. Daewoong Pharmaceutical Co Ltd Corporation Information
Table 123. Daewoong Pharmaceutical Co Ltd Description and Major Businesses
Table 124. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 125. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Daewoong Pharmaceutical Co Ltd Recent Developments
Table 127. Dermala Inc Corporation Information
Table 128. Dermala Inc Description and Major Businesses
Table 129. Dermala Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 130. Dermala Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Dermala Inc Recent Developments
Table 132. Helix BioMedix Inc Corporation Information
Table 133. Helix BioMedix Inc Description and Major Businesses
Table 134. Helix BioMedix Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 135. Helix BioMedix Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. Helix BioMedix Inc Recent Developments
Table 137. Novan Inc Corporation Information
Table 138. Novan Inc Description and Major Businesses
Table 139. Novan Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 140. Novan Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Novan Inc Recent Developments
Table 142. Sol-Gel Technologies Ltd Corporation Information
Table 143. Sol-Gel Technologies Ltd Description and Major Businesses
Table 144. Sol-Gel Technologies Ltd Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 145. Sol-Gel Technologies Ltd Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Sol-Gel Technologies Ltd Recent Developments
Table 147. TGV-Laboratories Corporation Information
Table 148. TGV-Laboratories Description and Major Businesses
Table 149. TGV-Laboratories Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 150. TGV-Laboratories Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. TGV-Laboratories Recent Developments
Table 152. Viamet Pharmaceuticals Inc Corporation Information
Table 153. Viamet Pharmaceuticals Inc Description and Major Businesses
Table 154. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 155. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Viamet Pharmaceuticals Inc Recent Developments
Table 157. Vyome Biosciences Pvt Ltd Corporation Information
Table 158. Vyome Biosciences Pvt Ltd Description and Major Businesses
Table 159. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 160. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Vyome Biosciences Pvt Ltd Recent Developments
Table 162. Key Raw Materials Lists
Table 163. Raw Materials Key Suppliers Lists
Table 164. Dermatomycoses Drug Distributors List
Table 165. Dermatomycoses Drug Customers List
Table 166. Dermatomycoses Drug Market Trends
Table 167. Dermatomycoses Drug Market Drivers
Table 168. Dermatomycoses Drug Market Challenges
Table 169. Dermatomycoses Drug Market Restraints
Table 170. Research Programs/Design for This Report
Table 171. Key Data Information from Secondary Sources
Table 172. Key Data Information from Primary Sources
List of Figures
Figure 1. Dermatomycoses Drug Product Picture
Figure 3. Global Dermatomycoses Drug Market Share by Type in 2021 & 2028
Figure 3. BB-2603 Product Picture
Figure 4. Clotrimazole Product Picture
Figure 5. Dapaconazole Product Picture
Figure 6. Others Product Picture
Figure 7. Global Dermatomycoses Drug Market Share by Application in 2021 & 2028
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Others
Figure 11. Dermatomycoses Drug Report Years Considered
Figure 12. Global Dermatomycoses Drug Sales 2017-2028 (K Units)
Figure 13. Global Dermatomycoses Drug Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Dermatomycoses Drug Revenue 2017-2028 (US$ Million)
Figure 15. Global Dermatomycoses Drug Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Dermatomycoses Drug Sales Market Share by Region (2017-2022)
Figure 17. Global Dermatomycoses Drug Sales Market Share by Region (2023-2028)
Figure 18. North America Dermatomycoses Drug Sales YoY (2017-2028) & (K Units)
Figure 19. North America Dermatomycoses Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Dermatomycoses Drug Sales YoY (2017-2028) & (K Units)
Figure 21. Europe Dermatomycoses Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Dermatomycoses Drug Sales YoY (2017-2028) & (K Units)
Figure 23. Asia-Pacific Dermatomycoses Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Dermatomycoses Drug Sales YoY (2017-2028) & (K Units)
Figure 25. Latin America Dermatomycoses Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Dermatomycoses Drug Sales YoY (2017-2028) & (K Units)
Figure 27. Middle East & Africa Dermatomycoses Drug Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Dermatomycoses Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Dermatomycoses Drug in the World: Market Share by Dermatomycoses Drug Revenue in 2021
Figure 30. Global Dermatomycoses Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Dermatomycoses Drug Sales Market Share by Type (2017-2028)
Figure 32. Global Dermatomycoses Drug Revenue Market Share by Type (2017-2028)
Figure 33. Global Dermatomycoses Drug Sales Market Share by Application (2017-2028)
Figure 34. Global Dermatomycoses Drug Revenue Market Share by Application (2017-2028)
Figure 35. North America Dermatomycoses Drug Sales Market Share by Type (2017-2028)
Figure 36. North America Dermatomycoses Drug Revenue Market Share by Type (2017-2028)
Figure 37. North America Dermatomycoses Drug Sales Market Share by Application (2017-2028)
Figure 38. North America Dermatomycoses Drug Revenue Market Share by Application (2017-2028)
Figure 39. North America Dermatomycoses Drug Sales Share by Country (2017-2028)
Figure 40. North America Dermatomycoses Drug Revenue Share by Country (2017-2028)
Figure 41. U.S. Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Dermatomycoses Drug Sales Market Share by Type (2017-2028)
Figure 44. Europe Dermatomycoses Drug Revenue Market Share by Type (2017-2028)
Figure 45. Europe Dermatomycoses Drug Sales Market Share by Application (2017-2028)
Figure 46. Europe Dermatomycoses Drug Revenue Market Share by Application (2017-2028)
Figure 47. Europe Dermatomycoses Drug Sales Share by Country (2017-2028)
Figure 48. Europe Dermatomycoses Drug Revenue Share by Country (2017-2028)
Figure 49. Germany Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 50. France Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Dermatomycoses Drug Sales Market Share by Type (2017-2028)
Figure 55. Asia Pacific Dermatomycoses Drug Revenue Market Share by Type (2017-2028)
Figure 56. Asia Pacific Dermatomycoses Drug Sales Market Share by Application (2017-2028)
Figure 57. Asia Pacific Dermatomycoses Drug Revenue Market Share by Application (2017-2028)
Figure 58. Asia Pacific Dermatomycoses Drug Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Dermatomycoses Drug Revenue Share by Region (2017-2028)
Figure 60. China Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 63. India Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 65. Taiwan Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 69. Philippines Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 70. Latin America Dermatomycoses Drug Sales Market Share by Type (2017-2028)
Figure 71. Latin America Dermatomycoses Drug Revenue Market Share by Type (2017-2028)
Figure 72. Latin America Dermatomycoses Drug Sales Market Share by Application (2017-2028)
Figure 73. Latin America Dermatomycoses Drug Revenue Market Share by Application (2017-2028)
Figure 74. Latin America Dermatomycoses Drug Sales Share by Country (2017-2028)
Figure 75. Latin America Dermatomycoses Drug Revenue Share by Country (2017-2028)
Figure 76. Mexico Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 77. Brazil Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 78. Argentina Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 79. Middle East and Africa Dermatomycoses Drug Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Dermatomycoses Drug Revenue Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Dermatomycoses Drug Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Dermatomycoses Drug Revenue Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Dermatomycoses Drug Sales Share by Country (2017-2028)
Figure 84. Middle East and Africa Dermatomycoses Drug Revenue Share by Country (2017-2028)
Figure 85. Turkey Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 86. Saudi Arabia Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 87. U.A.E Dermatomycoses Drug Revenue (2017-2028) & (US$ Million)
Figure 88. Dermatomycoses Drug Value Chain
Figure 89. Dermatomycoses Drug Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
Key Players
Anacor Pharmaceuticals Inc
Biolab Farmaceutica Ltda
Blueberry Therapeutics Ltd
Daewoong Pharmaceutical Co Ltd
Dermala Inc
Helix BioMedix Inc
Novan Inc
Sol-Gel Technologies Ltd
TGV-Laboratories
Viamet Pharmaceuticals Inc
Vyome Biosciences Pvt Ltd

Speak with Analyst

I'm not a robot
The market research report includes specific segments by region (country), i.e. North America, Europe, Asia Pacific, South America, Middle East and Africa
The market report provides global companies with an opportunity to enter new markets, invest in new sectors, analyze consumer reactions, investigate global competition, and ultimately make smart investments.
This report covers the latest market developments in terms of acquisitions, growth strategies, joint ventures and collaborations, new product launches, and more on industry.
We can provide customization on reports prior to the sale. If you need customization we request you to provide specific details on customization prior to the dispatch. This is because we move fast with your queries as it requires a lot of diligence. There will be additional charges for customization once the report is dispatched to you and will be treated as post-sales query.
Requesting a Sample copy of the report from Xcellent Insights is hassle-free! You can either request it from the report page or call our sales Executive at US: +1 408 627 7717 /UK: +44 208 638 6439 and share/discuss your requirements. Our Team will share the sample copy of the report with you within 12 Working Hours / Shortly.
Ordering a report from Xcellent Insights is hassle-free! You can select a licence type that suits your requirement and proceed to checkout. It will redirect you to the payment gateway with a list of payment options. Be rest assured that we do not store the payment details. Once we receive the payment, a confirmation email will be sent on your registered mail id with details on the report delivery timeline. You can also get your order placed through our business development executives and they will guide you thoroughly.
  • You should buy this report from Xcellent Insights for a better clarity on market scenarios.
  • The market report has been prepared using a pragmatic approach to suit your needs.
  • We have an extensive library of reports that can help you understand the market landscape and make informed decisions about your business.
  • Additionally, the reports are written by experienced analysts who have a deep understanding of the market and the latest trends.
  • Besides, customization is a value-added service if you decide to opt.
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Impress clients new and existing with elite construction brochures. Impress clients new and existing with elite construction.
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Impress clients new and existing with elite construction brochures. Impress clients new and existing with elite construction.
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Impress clients new and existing with elite construction brochures. Impress clients new and existing with elite construction.
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Impress clients new and existing with elite construction brochures. Impress clients new and existing with elite construction.
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Impress clients new and existing with elite construction brochures. Impress clients new and existing with elite construction.
Leverage agile frameworks to provide a robust synopsis for high level overviews. Iterative approaches to corporate strategy foster collaborative thinking to further the overall value proposition. Impress clients new and existing with elite construction brochures. Impress clients new and existing with elite construction.
Why Choose Us:
  • Extensive Library of Reports.
  • Identify the clients' needs.
  • Pragmatic Research Approach.
  • Clarity on Market Scenarios.
  • Tailor-Made Solutions.

  • Expert Analysts Team.
  • Competitive and Fair Prices.

Clientele:
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
client-logos
Get in Touch